Recombinant non-structural polyprotein 3AB-based serodiagnostic strategy for FMD surveillance in bovines irrespective of vaccination

► Recombinant nonstructural protein 3AB-based indirect ELISA for FMD serosurveillance. ► Diagnostic sensitivity and specificity of 96% and 96.4–99.1%, respectively. ► Detects antibodies from 10 to 900 days postinfection in experimental cattle. ► Higher diagnostic sensitivity than a commercial 3ABC E...

Full description

Saved in:
Bibliographic Details
Published inJournal of virological methods Vol. 177; no. 2; pp. 184 - 192
Main Authors Mohapatra, Jajati K., Pandey, Laxmi K., Sanyal, Aniket, Pattnaik, Bramhadev
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier B.V 01.11.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:► Recombinant nonstructural protein 3AB-based indirect ELISA for FMD serosurveillance. ► Diagnostic sensitivity and specificity of 96% and 96.4–99.1%, respectively. ► Detects antibodies from 10 to 900 days postinfection in experimental cattle. ► Higher diagnostic sensitivity than a commercial 3ABC ELISA kit in late phases of infection. ► Occasional postvaccinal 3AB-antibody response warrants more pure vaccines. In India, the proportion of bovines vaccinated against foot-and-mouth disease (FMD) is increasing since the implementation of the Government supported ‘FMD Control Programme’, and non-structural protein (NSP)-based serological assays for discriminating between antibodies induced by infection or vaccination (DIVA) could be useful. The FMD virus NSP 3AB was expressed in a prokaryotic system and an indirect ELISA (r3AB 3 I-ELISA) was developed and validated as a screening assay for detecting virus in vaccinated bovines. The diagnostic sensitivity of the assay was estimated to be 96%, while the diagnostic specificity varied between the naïve and vaccinates as 99.1% and 96.4%, respectively. This assay could detect antibodies to 3AB (3AB-Ab) from 10 to as late as 900 days post-infection in cattle infected experimentally. The “in-house” assay demonstrated higher sensitivity than a commercial 3ABC ELISA kit particularly with samples obtained from the late stages of infection. Transient post-vaccinal 3AB-Ab response could be detected in one of the three commercial vaccines during the six-month vaccination regimen, which emphasizes the fact that for a DIVA-compatible diagnostic strategy to be a realistic option, all vaccines need to be quality checked for the NSP content.
Bibliography:http://dx.doi.org/10.1016/j.jviromet.2011.08.006
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0166-0934
1879-0984
DOI:10.1016/j.jviromet.2011.08.006